Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fennec Pharmaceuticals Inc. (FENC) Q1 2026 Earnings Call Transcript
Adherex Technologies Q1 Earnings Call Highlights
Adherex Technologies Inc. (FENC) Beats Q1 Earnings and Revenue Estimates
Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026
FENC Secures Second Consecutive Inclusion in S&P Global Dow Jones Best in Class Emerging Markets Index
Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center
Adherex Technologies Inc. (NASDAQ:FENC) Receives Average Rating of “Moderate Buy” from Brokerages
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Adherex Technologies (FENC) to Release Earnings on Wednesday
Fennec Pharmaceuticals Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Fennec Pharmaceuticals Inc. (FENC) Q4 2025 Earnings Call Transcript
Adherex Technologies Inc. (FENC) Reports Q4 Loss, Misses Revenue Estimates
Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Fennec Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026
Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute
Adherex Technologies Inc. (FENC) Earnings Expected to Grow: What to Know Ahead of Q4 Release
Fennec Pharmaceuticals Presents Real World Data Supporting the Integration and Clinical Use of PEDMARK® in Treating Adults with Head & Neck Cancers
Brokerages Set Adherex Technologies Inc. (NASDAQ:FENC) PT at $14.50
Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)
Adherex Technologies Inc. (NASDAQ:FENC) Given Consensus Recommendation of “Hold” by Analysts
Fennec Pharmaceuticals: A Compelling Single-Asset Growth Story For 2026
Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors
Pedmark Delivers In Japan Study — Less Hearing Loss, Same Cancer-Fighting Power
Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss
Brokerages Set Adherex Technologies Inc. (NASDAQ:FENC) Price Target at $13.33
Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference
Fennec Pharmaceuticals Announces Completion Of Full Debt Redemption
Fennec Pharmaceuticals Announces Closing of Offering of Common Shares
Fennec Pharmaceuticals Announces Private Offering of Common Shares in Canada
Fennec Pharmaceuticals Announces Pricing of Offering of Common Shares
Adherex Technologies Inc. (FENC) Reports Q3 Loss, Tops Revenue Estimates
Fennec Pharmaceuticals Announces Proposed Offering of Common Shares
Adherex Technologies Inc. (FENC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
New Strong Sell Stocks for Oct. 15th
Is the Options Market Predicting a Spike in Adherex Technologies Stock?
Fennec Pharmaceuticals Inc. (FENC) Q2 2025 Earnings Call Transcript
Adherex Technologies Inc. (FENC) Reports Q2 Loss, Beats Revenue Estimates
Fennec Pharmaceuticals Reports Second Quarter 2025 Financial Results And Provides Business Update
Fennec Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 14, 2025
Recent Price Trend in Adherex Technologies (FENC) is Your Friend, Here's Why
Fennec Announces Results of Annual Meeting
Fennec Pharmaceuticals Inc. (FENC) Q1 2025 Earnings Call Transcript
Adherex Technologies Inc. (FENC) Reports Q1 Loss, Tops Revenue Estimates
Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025